Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

NCT: NCT05820087 · ACTIVE_NOT_RECRUITING

NCT IDNCT05820087
StatusACTIVE_NOT_RECRUITING
Start Date2024-01-04
Completion2030-07
SponsorHistoSonics, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors.

Frequently Asked Questions

What is The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)?

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) is a clinical trial registered under NCT05820087. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05820087?

The current status of NCT05820087 (The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)) is: ACTIVE_NOT_RECRUITING.

When did The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) start?

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) started on 2024-01-04.

Related Devices

K233466Edison SystemHistoSonics, Inc. K241902Edison SystemHistoSonics, Inc. K252947HistoSonics® Planning ToolHistoSonics, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑